These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20730610)

  • 1. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
    Pakravan N; Hashemi SM; Hassan ZM
    Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.
    Pakravan N; Hassan ZM
    Cell Stress Chaperones; 2011 Jul; 16(4):449-57. PubMed ID: 21359667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.
    Pakravan N; Soudi S; Hassan ZM
    Cell Stress Chaperones; 2010 Sep; 15(5):631-8. PubMed ID: 20224916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GP96 C-terminal improves Her2/neu DNA vaccine.
    Pakravan N; Soleimanjahi H; Hassan ZM
    J Gene Med; 2010 Apr; 12(4):345-53. PubMed ID: 20232284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.
    Fu Q; Wu Y; Yan F; Wang N; Wang W; Cao X; Wang Y; Wan T
    Cell Mol Immunol; 2011 Sep; 8(5):424-32. PubMed ID: 21785448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu.
    Lin CC; Chou CW; Shiau AL; Tu CF; Ko TM; Chen YL; Yang BC; Tao MH; Lai MD
    Mol Ther; 2004 Aug; 10(2):290-301. PubMed ID: 15294176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
    Singh R; Dominiecki ME; Jaffee EM; Paterson Y
    J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
    Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
    Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.
    Pishraft-Sabet L; Kosinska AD; Rafati S; Bolhassani A; Taheri T; Memarnejadian A; Alavian SM; Roggendorf M; Samimi-Rad K
    Arch Virol; 2015 Jan; 160(1):141-52. PubMed ID: 25348271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS; Morrison SL; Penichet ML
    Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.
    Pakravan N; Langroudi L; Hajimoradi M; Hassan ZM
    Cell Stress Chaperones; 2010 Nov; 15(6):977-84. PubMed ID: 20544406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
    Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.
    Wang J; Wang X; Chen Y; Wan M; Xiang Z; Wu X; Wei H; Wang L; Zhang P; Wang L; Yu Y
    Tumour Biol; 2013 Feb; 34(1):193-201. PubMed ID: 23055194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
    Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
    Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
    Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.
    Bhattachary R; Bukkapatnam R; Prawoko I; Soto J; Morgan M; Salup RR
    Int Immunopharmacol; 2002 May; 2(6):783-96. PubMed ID: 12095169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.